Arcutis Biotherapeutics, Inc. - ARQT STOCK NEWS

Arcutis Biotherapeutics reported strong Q2 2024 financial results, with net product revenues of $30.9M for the ZORYVE franchise, representing a 547% increase year-over-year and 43% growth quarter-over-quarter. The company saw improved gross-to-net (GTN) margins, now in the high 50% range. Arcutis entered a co-promotion agreement with Kowa Pharmaceuticals to expand ZORYVE's reach in primary care and pediatric offices. They also submitted an sNDA for ZORYVE foam for scalp and body psoriasis treatment. The company amended its $200M term-loan, improving financial flexibility. Despite strong sales growth, Arcutis reported a net loss of $52.3M for Q2 2024, with cash and equivalents of $363.1M as of June 30, 2024.

Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology innovations, has reported the grant of 38,000 restricted stock units to four newly hired employees. The awards were approved by the Compensation Committee of Arcutis' Board of Directors under the company's 2022 Inducement Plan, with a grant date of August 1, 2024.

These stock units are designed as an inducement for new employees joining Arcutis, in compliance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units have a four-year vesting schedule, with 25% vesting on each annual anniversary of the vesting commencement date, contingent on continuous employment with Arcutis.

Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology innovations, has announced its plans to release second quarter 2024 financial results on August 14, 2024. The company will disclose its financial performance and provide a business update after the U.S. financial markets close on that day. Additionally, Arcutis will host a conference call and webcast at 4:30 p.m. ET to discuss the results. Investors and interested parties can access the live webcast and presentation materials through the 'Events' section of the company's website. An archived version of the webcast will be made available on the Arcutis investor website following the conference call.

Arcutis Biotherapeutics (Nasdaq: ARQT) has announced a co-promotion agreement with Kowa Pharmaceuticals America for ZORYVE® (roflumilast). This partnership will leverage Kowa's 200-person primary care sales force to promote ZORYVE cream and foam to primary care practitioners and pediatricians for all FDA-approved indications. The agreement aims to expand ZORYVE's total addressable market, providing access to a significant portion of the 7.4 million patients treated outside dermatology offices.

Key points of the agreement include:

• 5-year term with Kowa promoting ZORYVE in priority position
• Arcutis retains responsibility for manufacturing and dermatology sales
• Arcutis will recognize all revenue and pay Kowa a commission on sales
• Expected to drive incremental revenue while maintaining Arcutis' focus on dermatology

Arcutis Biotherapeutics (ARQT) has launched ZORYVE® (roflumilast) cream 0.15% for treating mild to moderate atopic dermatitis in adults and children aged 6 and older in the US. This once-daily, steroid-free cream offers rapid disease clearance and significant itch reduction, designed for long-term disease control. ZORYVE can be used anywhere on the body for any duration to maintain clear skin.

The product is now commercially available in pharmacies, with immediate insurance coverage through two commercial PBM contracts. Arcutis emphasizes responsible pricing and affordable access, offering patient support programs including the ZORYVE® Direct Program and Arcutis CaresTM patient assistance program.

Arcutis Biotherapeutics (Nasdaq: ARQT) has submitted a supplemental New Drug Application (sNDA) for ZORYVE® (roflumilast) foam to the FDA for treating scalp and body psoriasis in adults and adolescents ages 12 and over. The once-daily foam significantly improved both scalp and body psoriasis in Phase 2b and Phase 3 trials, with 67% of participants achieving Scalp-Investigator Global Assessment Success at 8 weeks. The treatment also showed rapid reduction in scalp itch within 24 hours and demonstrated a favorable safety profile.

This submission marks Arcutis' fifth topical roflumilast regulatory submission in the U.S. in less than three years. The company believes ZORYVE foam has great potential for adoption in scalp and body psoriasis, building on its success in seborrheic dermatitis treatment.

Arcutis Biotherapeutics (Nasdaq: ARQT) has announced a virtual Key Opinion Leader (KOL) event to discuss the recent FDA approval of ZORYVE® (roflumilast) cream 0.15% for treating mild to moderate atopic dermatitis (AD) in adults and children aged 6 and above. The event, scheduled for July 29, 2024, at 8:30am ET, will feature a leading dermatology expert who will address the unmet needs and current treatment landscape for AD. The discussion will highlight ZORYVE's differentiating features and Arcutis' commercialization plans for this newly approved treatment. This event marks a significant milestone for Arcutis in the immuno-dermatology field, potentially impacting their market position and future revenue streams.

Arcutis Biotherapeutics announced that the FDA approved ZORYVE (roflumilast) cream 0.15% for treating mild to moderate atopic dermatitis (AD) in patients aged six and older.

ZORYVE, a steroid-free cream, reduces itch and provides rapid disease clearance, showing efficacy and safety in up to 56 weeks of treatment.

Clinical trials demonstrated significant improvements, with 69% of patients showing at least a 50% reduction in symptoms within four weeks.

This marks Arcutis' third FDA approval in two years, with the product available by the end of July.

Arcutis Biotherapeutics has communicated with the FDA regarding its sNDA for roflumilast cream 0.15% aimed at treating mild to moderate atopic dermatitis in adults and children as young as six. The FDA is finalizing the action letter without extending the PDUFA goal date of July 7, 2024. The FDA has not requested additional information, highlighting the completeness of Arcutis' submission. Arcutis anticipates receiving the action letter soon and aims to introduce this innovative treatment to millions suffering from atopic dermatitis.